Tempus ai today
As of 02/14/2025 04:00 pm
- 52 weeks
- 22.89 dollars
▼
91.45 dollars
- The target price
- 58.55 dollars
Tempus ai Nasdak: Tim He is a pioneer in fine medicine and artificial intelligence (AI) in the health care sector. The price of the Tempus AI share increased, as the gains of more than 160 % in the past month and about 150 % on an annual basis, causing increased interest to investors.
This rapid growth raises an important question: Does this mutation accurately reflect the value of the company and its capabilities for growth, or is it an unsustainable trend moved by the excessive market enthusiasm?
Ambry acquisition: a calculated step for market domination
The investor’s confidence has been greatly strengthened in $ 375 million in cash and $ 225 million in stocks, greatly reinforced investor confidence in Tempus AI AIS of Ambry Genetics, which was completed on February 3, 2025, compared to $ 375 million in cash and $ 225 million in Arrows. This strategic step enhances the position of Tempus AI in the market and service offers by expanding its diagnostic capabilities, especially in examining genetic cancer and genetic tests for various diseases outside the tumors.
The experience of genetics in pediatrics, rare diseases, immunity, reproductive health for women, and cardiology are the diversity of TEMPUS AI reaching new groups of patients and potential revenue flows. Market analysts and investors view this acquisition as a synergy alignment, creating a more powerful and comprehensive platform for Tempus AI in accurate diagnosis and data -based health care solutions.
Promising financial expectations for Tempus AI
The promising financial path of Tempus AI adds to positive expectations. Initial results of the fiscal year 2024 indicate the growth of health revenues of about 30 % year on an annual basis, reaching nearly $ 693 million. More impressive, 2024 revenues in the fourth quarter are estimated at about $ 200 million, and it represents an increase of 35 % on an annual basis. In addition to expanding revenues, Tempus AI has shown a continuous improvement in the modified Ebitda, a main scale indicating the enhancement of operational efficiency and movement towards profitability.
The market is eagerly awaiting the full profit report to be released on February 24, 2025, with high expectations to confirm these positive initial numbers and more ideas about the company’s financial health. The revenue guidelines for the fiscal year 2024, which determines about 700 million, enhances investor confidence in the ability of Tempus AI to maintain growth momentum and achieve their financial goals. This positive financial path is a major factor that supports the recent estimate of the share.
New boundaries in careful medicine
Tempus AI has launched many new products, indicating its commitment to innovation, expanding the market and contributing to the positive investor morale. The first full genome sequence of the company (WGS), XH, which initially focuses on blood malignant tumors, focuses a comprehensive discovery, and perhaps unifying multiple tests in one.
The improved Tempus One Genai platform, equipped with new typical capabilities (LLM), displays the leadership of Tempus AI in the application of artificial intelligence to uncontrolled health care data, and provides advanced tools to support clinical decision and research. The national launch of the XT CDX, a test of the next generation sequence of the next genes approved by the FDA (FDA), provides doctors with a strong and organizational diagnostic tool for solid tumors, which increases the hardening of the Tempus AI mode in the clinical diagnostic market.
Finally, the availability of Olivia at the country level, which is an application composed of patients’ personal health for patients, is a diversification of Tempus AI to the patient’s focus solutions, which expands its scope beyond the healthcare providers and pharmaceutical companies directly to the patient’s community.
Strategic alliances that feed the growth of artificial intelligence
Strategic cooperation and partnerships increases the inflation of the surrounding bullish narration of artificial intelligence. Cooperation with the Innovation of the Innovation of Lymphoma (IFLI) is highlighted to develop a data library in the real world for porous lymphatic tumor commitment to Tempus AI to the targeted research in specific disease areas and its ability to attract partnerships with specialized organizations.
This cooperation does not expand the assets of Tempus AI only in a critical field of tumors, but also verifies its platform and analytical capabilities in the eyes of existing research institutions. While the details related to the Arterra partnership are still limited, the main announcement of cooperation to expand access to artificial intelligence cancer test indicates more strategic expansions in synergy, which enhances the company’s perception of the construction of a wide and strong ecosystem.
These partnerships are seen by investors as the external verification of Tempus AI technology and strategic guidance, which increases the enhancement of the positive investment thesis.
Does the price of Tempus AI work before the basics?
TEMPUS AI stocks today
58.55 dollars
Moderate purchase
Based on 12 analyst classifications
| High expectations | $ 74.00 |
|---|---|
| Average expectations | 58.55 dollars |
| Low expectations | 44.00 dollars |
Details of the expected expectations of Amnesty International shares
The last reduction of Tempus AI from performance to marketing by William Blair, due to the evaluation concerns, indicates a possible estimate risk. This reduction indicates that the share price may have exceeded the levels supported by the company’s basics and prospects for the short term. In addition, the price of the consensus analyst of $ 58.55 indicates a possible negative aspect of more than 30 % of the current share price.
The scope of the goals of the price supports this perspective, with all goals down below the current market price. Although the consensus classification is still a moderate purchase, the presence of suspension classifications and the important negative aspect that the price goals indicate indicates a more cautious analyst’s expectations. Investors must carefully consider analysts’ doubts regarding evaluation.
The newly interior sales activity by Key Tempus AI’s CEOs adds another layer of complexity to the evaluation question. The files of early February reveal that four of the different C-Suite executives have sold large sums of Tempus AI shares, with a total of about $ 12.5 million.
Although sales from the inside can occur for different personal financial reasons and does not automatically indicate a lack of confidence in the company, it calls for the investor’s attention, especially when coinciding with evaluation concerns and increasing dramatic shares. In the context of analyzing suspicions about the evaluation of Tempus AI, the sale can be explained from the important interior as an indication that those who have a deeper vision in the company’s horizons may think that the share price has reached an unnecessary peak or that achieving profits at the current levels is a warning of the financial step .
Investors should consider this interior sales activity as another data point that contributes to the general image of the potential evaluation risks of Tempus AI.
Investing in conflicting signs: a cautious approach
Tempus AI offers a convincing investment opportunity with great growth capabilities. However, the current share price may be exaggerated, and the sale increases from the inside. Investors must weigh positive stimuli against the risk of evaluation and analysts’ concerns. The profit report on February 24 will be very important in determining whether the current evaluation is justified or not.
The financial results and management directions will provide major data points for performance evaluation and growth momentum. Investors must also monitor analyst evaluations and targeted price modifications after issuing profits. Investing in Tempus AI at current levels requires recognition of certainty and volatility. It is recommended to use a cautious approach with comprehensive due care and continuous monitoring.
Before you think about Tempus AI, you will want to hear this.
Marketbeat follows the best research analyst at Wall Street, the best performance in Wall Street and the stocks they recommend to their customers on a daily basis. Marketbeat has selected the five shares whom the top analysts quietly whispered to their customers to buy now before wiping the broader market … and not Tempus AI was on the list.
While Tempus AI currently has a “moderate purchase” classification among analysts, analysts from senior exporters believe that these five stocks buy better.
Show the five stocks here
Enter your email address and we will send you the Marketbeat menu that includes seven best pension shares and why you should be in your wallet.
